Regeneron Pharmaceuticals Inc. recently unveiled its latest corporate presentation, highlighting significant advancements in their R&D pipeline and financial performance for Q2 2025. The company reported total revenues of $3.68 billion and a non-GAAP EPS of $12.89 for the second quarter. Notable R&D advancements include extended dosing intervals for certain treatments and approvals for new uses of existing drugs. Regeneron's oncology strategy focuses on leveraging the immune system to combat cancer through five classes of immunomodulatory agents, with several demonstrating potentially best-in-class clinical efficacy. The presentation also underscored Regeneron's commitment to innovation with their Genetic Medicines Program, which customizes genetics technology for therapeutic applications. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.